PROFESSOR ISA ODIDI, B.Sc., M.Sc., Ph.D. CHAIRMAN & CEO
it appears Isa Odidi is running unde the New Democratic banner for Nigeria
ND Philosophy The ND is committed to the view that the dignity of each individual man and woman is the cardinal principle of democratic society and the primary purpose of all political organization and activity in such a society.
It is dedicated to the principles of: individual freedom, responsibility and human dignity in the framework of a just society, and political freedom in the framework of meaningful participation by all persons. The ND is bound by the Constitution and is committed to the pursuit of equality of opportunity for all persons, to the enhancement of our unique and diverse ethnicity all persons, to the enhancement of our unique and diverse cultural community, and to the preservation of the Nigerian identity in a global society.
In accordance with this philosophy, the ND subscribes to the fundamental rights and freedoms of persons under the rule of law and commits itself to the protection of these essential values and their constant adaptation to the changing needs of modern Nigerian society.
The ND recognizes that human dignity in a democratic system requires that all citizens have access to full information concerning the policies and leadership of the Party, the opportunity to participate in open and public assessment of such means, such modifications of policies and leadership as they deem desirable to promote the political, economic, social, cultural and general well-being of Nigerians.
To realize this objective, the ND strives to provide a flexible and democratic structure whereby all Nigerians can obtain such information, participate in such assessment and militate for such reform through open communications, free dialogue and participatory action both electoral and non-electoral.
Podcast: Prof Isa Odidi (Part 1) "This case is not about me- its about all Nigerians in Diaspora" The Chairman and presidential flag-bearer of New Democrats Party (NDP), Prof Isa Odidi talks to NVS on why he wants to be the President in 2007 and why every Nigerian with dual citizenship and Nigerians in Diaspora should pay close attention to his court case against INEC Length: 15 minutes
Professor Isa Odidi is a founder and one of the principals of IntelliPharmaCeutics, and serves as Chairman of the Board, ChiefExecutive Officer, Co-Chief Scientific Officer and Chair of Scientific Advisory Board.
From 1995 to 1998, Professor Isa Odidi held positions, first as Director, then as Vice President, of Research, Drug Development and New Technologies at Biovail Corporation International (now Biovail Corporation), a drug delivery company. During this time, Professor Odidi developed several blockbuster drugs, including supergenerics of the very difficult to duplicate Adalat CC (Bayer) and Procardia XL (Pfizer).
In the pharmaceutical industry, Professor Odidi is highly regarded for his entrepreneurial acumen, something rare for a scientist. Professor Odidi is also a highly respected innovator and inventor with a long history of success. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles and textbooks.
Prior to 1995, Professor Odidi held senior positions in academia and in the pharmaceutical and health care industries. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine, California, U.S.A.
Professor Isa Odidi received his B.Sc. degree in Pharmacy, from Ahmadu Bello University, and his M.Sc., Pharmaceutical Technology and Ph.D Pharmaceutics degrees from the University of London, England. Professor Odidi is a graduate of the highly regarded Western Executive Management Program at the Ivey School of Business, University of Western Ontario. He is also a member of University of Toronto, Rotman's School of Business Class of 2001.
Professor Odidi's role in the company is to provide inventive approaches to drug formulation, strategic direction, managerial and scientific guidance, and to oversee the widest commercialization of the company's considerable scientific capabilities
IntelliPharmaCeutics Corp., of Toronto, Canada, is the Canadian operating affiliate of IntelliPharmaCeutics Ltd., a Delaware corporation. At present, the companies are in the process of becoming fully reporting companies under United States securities laws. An SB-2 Registration Statement to register the common shares of IntelliPharmaCeutics Ltd. will be filed with the SEC in the first quarter of 2006. In the future, a public offering in the United States, Canada, or the United Kingdom may be pursued.
THE NEXT DIMENSION COMPANY IntelliPharmaCeutics represents a success story like no other. Since its inception in 1998, the company has become a key global player in the pharmaceutical market. Through flourishing business relations with some of the world’s largest and most demanding clients, IntelliPharmaCeutics continues to exceed expectations.
IntelliPharmaCeutics is at the forefront of the design and the development of controlled release drugs. The core drug delivery technology employed by IntelliPharmaCeutics is the patented HYPERMATRIX technology which is a revolutionary drug delivery platform. Utilizing this technology, our scientists are able to provide life cycle management or new chemical entity delivery system solutions for virtually any small molecule. By recognizing that the key to remaining at the forefront of technological know-how requires housing the best and brightest corporate and scientific minds, IntelliPharmaCeutics will continue to make history in its unprecedented growth and delivery in the global pharmaceutical market.
CORPORATE & SCIENTIFIC MANAGEMENT PROFESSOR ISA ODIDI, B.Sc., M.Sc., Ph.D. CHAIRMAN & CEO
Professor Isa Odidi is a founder and one of the principals of IntelliPharmaCeutics, and serves as Chairman of the Board, ChiefExecutive Officer, Co-Chief Scientific Officer and Chair of Scientific Advisory Board.
From 1995 to 1998, Professor Isa Odidi held positions, first as Director, then as Vice President, of Research, Drug Development and New Technologies at Biovail Corporation International (now Biovail Corporation), a drug delivery company. During this time, Professor Odidi developed several blockbuster drugs, including supergenerics of the very difficult to duplicate Adalat CC (Bayer) and Procardia XL (Pfizer).
In the pharmaceutical industry, Professor Odidi is highly regarded for his entrepreneurial acumen, something rare for a scientist. Professor Odidi is also a highly respected innovator and inventor with a long history of success. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles and textbooks.
Prior to 1995, Professor Odidi held senior positions in academia and in the pharmaceutical and health care industries. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine, California, U.S.A.
Professor Isa Odidi received his B.Sc. degree in Pharmacy, from Ahmadu Bello University, and his M.Sc., Pharmaceutical Technology and Ph.D Pharmaceutics degrees from the University of London, England. Professor Odidi is a graduate of the highly regarded Western Executive Management Program at the Ivey School of Business, University of Western Ontario. He is also a member of University of Toronto, Rotman's School of Business Class of 2001.
Professor Odidi's role in the company is to provide inventive approaches to drug formulation, strategic direction, managerial and scientific guidance, and to oversee the widest commercialization of the company's considerable scientific capabilities.
News 
Market Data 
Discover 
AI
